How to Select the Right Institute & Program for your Career

 Selecting the right institute and program is key to success in your professional life. The right program from the right institute can help us in reaching the top of your career. At the same time selecting a non-accredited program from a non-authorized institute without a proper background check or just based on lucrative and false promises or low fee offers may ruin your career or may force you to reinvest your money and time to study the same program again, leaving you to fall behind in the race of life. Thus, it is very important to analyze the program and institute on various parameters before enrolling into that. Today we will discuss a few factors, which may be taken into consideration or avoided while selecting any program or institute.

PROGRAM

While searching for any Job/Career oriented program, it must be checked whether the program is accredited by any Government authority or some International organization of repute with global acceptance. It should also be verified, whether the program is aligned with industry requirements and accepted by them or not. The simplest way is to check the placement track record of the institute. Here you can analyze the acceptance of the program of the institute by companies

INSTITUTE

In the present market every organization are claiming to be the best, even with very less or no track record. It becomes very important to do a fact check of the institute before enrolling into their program. There are a few parameters any institute must be tested upon.

• Background : The background of any institute matters the most. The people behind the organization and their vision decides the foundation and ethics of the organization. You should check whether the founders are from a similar background and dedicated towards the industry or it’s just a money-making organization.
• History : The history of any organization is very important to be checked. The institute with a longer presence in the market proves its acceptance by the industry.
• Placement record : Always ask for the placement record of the institute. A good record reflects that its programs and well-designed and accepted by the industry and the team of trainers are well qualified.
• Feedback : Try to get feedback from the ex-students and industry people, who have been part of the institute. They are the people who give you a clear idea about the institute.
• Accreditation : This is the most important part of any program. A degree without any accreditation has no value in the real world. You must check for any govt or international accreditation of the program, the institute is offering.
• Industry Acceptance : Any program without acceptance from the industry is of no value. You must enquire, how well the students of the institute are absorbed/hired by the industry. Institutes with good placement records should easily be trusted. Students should not select any institute without proper placement records.

VALUE PROPOSITION

Any program/institute should never be rejected or selected just based on Fee. If you find the fee of any institute high, you should give it a consideration that why in this competitive world they have kept their fee high from others. There are various factors, which make the program higher. So rather than deciding just on fee, you should go to analyze the value proposition of the program. You should consider the following point before rejecting any program/institute.

• Program design
• Accreditation
• Faculty
• Live projects/Internship
• Industry linkages
• Placement Support
• Hiring Companies
• Salary offered after the program
• Career growth of the past students

PLACEMENT

This is the one of most important factor, which makes any program/institute eligible to be selected by students. You must ask the institute to share their recent placement records with the LinkedIn profile of the students. Institute must provide continuous placement assistance and arrange interviews with the recruiters. Ask their process of placements, cv writing, preplacement training, mock interviews, aptitude test prep and many other preplacement activities.

COUNSELLING

Counselling plays a very important role in selecting the right program or right career. The students should always consult a person with proper industry knowledge and exposure. They should never select any institute or program just on the advice of a friend or family, who are not an industry expert. Rather you should consult experts from any reputed institute or a career counsellor.

CERTIFICATION

If any organization is not offering a program with proper certification authorized by any Government body or accreditation organization, you should avoid enrolling in such programs.

PROGRAM ADD-ON

You should always look for some additional facilities/support with the program. Such as

• Multiple Certification
• Live projects
• Real Software training
• Industry Internship
• Pre-Placement training
• Assure Placement support

• 
  

Boost your Career with Clinical SAS

 The quality of human life is highly dependent on the most effective and safe medicines. Humankind has always been striving to develop the most effective & safe medicines. Drug discovery and development is a long, expensive, and complex process, which requires expert analysis of well-researched, properly organized & accurate information. Clinical trial data plays a pivotal role in the research and development of any drug. This resulted in the development of various research methodologies and techniques. Statistical analysis & presentation of research data is highly required for analysis of any drug development.

Statistical Analysis System (SAS) is the world leader in the statistical analysis of Clinical Data. It is a software system for data analysis and reports writing. SAS is a group of computer programs that work together to store data values and retrieve them, modify data, compute simple and complex statistical analyses, and create reports. It is the most demanded platform by the industry and the only accepted report-generating software by FDA.

Due to rapid growth in clinical trials, demand for the Clinical SAS programmers is increasing rapidly with global pharmaceutical companies and CROs are increasing outsourcing from India. Current size of the clinical trials market is US$49.8 billion which will grow to US$78.3 billion by 2030.

It is the right time to enter in the field of Clinical SAS. This career is not only the backbone of the Pharmaceutical industry but highly rewarding professionally for young professionals. If we talk about the entry level salary packages, in India the average starting salary package of a SAS Programmer is around INR 4.00 Lakh/Annum, which may grow at 15 – 20% per annum, whereas for the same role average salary in the USA it is $63,136/Annum.

This career option is available for people with a wide range of qualifications. Anyone who comes from a Medical, Pharmaceutical, Biology, Biotechnology, Mathematics, Statistics, or Engineering/Computing (Analytics) background can opt for this career.

This is a highly sophisticated career and requires a high level of theoretical and practical knowledge, so very intense and detailed training is highly required. Selection of right institute is very important. Institute should be able to provide you with the hands on training on SAS and Advanced Clinical SAS / CDISC, sound theoretical training and real time internship. It is important that you are trained on the real world data Institute must have senior experience industry trainers. Program should be certified and accredited by the government and international accreditation agencies.

Cliniminds is the leader in the life sciences skilling, training and consulting. Established in 2004, Cliniminds has trained over 9500 life sciences professionals. Cliniminds has robust 360 degree placement support program. Cliniminds is an innovative Clinical and Pharma research training institute providing a wide range of training solutions to students, pharmaceutical companies, CROs, and healthcare companies in India, USA, UK, and other parts of the world. Cliniminds have always been the first choice for students in selecting their training institutes and companies for hiring their employees.

For more information, please feel free to call at +91-9560102589 or mail us info@cliniminds.com Visit website – www.cliniminds.com

Current Trends In The Oncology Drugs Research

 Introduction

The field of oncology drug research has witnessed remarkable advancements in recent years, revolutionizing cancer treatment and patient outcomes. Rapid progress in understanding the underlying molecular mechanisms of cancer, along with the advent of new technologies and innovative drug development approaches, has propelled the development of novel therapeutic strategies. This article highlights the current trends in oncology drug research that are shaping the landscape of cancer treatment.

Immunotherapy

Immunotherapy is indeed a groundbreaking approach to cancer treatment that harnesses the power of the immune system to target and destroy cancer cells. It involves using substances, either naturally occurring or artificially created, to stimulate or enhance the body's immune response against cancer. There are different types of immunotherapy, each with its own mechanisms of action. Some commonly used forms of immunotherapy include:

1. Immune checkpoint inhibitors: These drugs block certain proteins on immune cells or cancer cells, which helps unleash the immune system's ability to recognize and attack cancer cells. Examples of checkpoint inhibitors include pembrolizumab and nivolumab.
2. CAR-T cell therapy: This personalized treatment involves collecting a patient's own immune cells (T cells), modifying them in a laboratory to express chimeric antigen receptors (CARs), and then infusing the modified cells back into the patient. CAR-T cells can recognize specific proteins on cancer cells and mount a targeted attack.
3. Tumor-infiltrating lymphocyte (TIL) therapy: TIL therapy involves isolating immune cells called lymphocytes from a patient's tumor, expanding them in the laboratory, and then reintroducing them into the patient. These activated lymphocytes can help recognize and attack the cancer cells.
4. Monoclonal antibodies: These are laboratory-produced antibodies that can recognize and bind to specific proteins found on cancer cells. This can mark the cancer cells for destruction by the immune system or directly inhibit their growth. Examples include trastuzumab for HER2-positive breast cancer and rituximab for certain types of lymphomas.

Immunotherapy has shown remarkable success in treating various types of cancers. Some patients have achieved long-lasting remissions, even in the advanced stages of the disease. However, it's important to note that not all patients respond equally to immunotherapy, and the effectiveness can vary depending on the type and stage of cancer.

Precision medicine, also known as personalized medicine or genomic medicine, is an approach to cancer treatment that utilizes genetic information to tailor medical decisions and interventions to individual patients. It involves analyzing a patient's unique genetic makeup, as well as other relevant factors such as lifestyle and environmental influences, to understand the specific characteristics of their cancer and determine the most effective treatment strategy.

1. Targeted therapies: These are drugs designed to specifically inhibit or block the activity of proteins or pathways that are essential for cancer cell growth and survival. Targeted therapies work by exploiting the specific genetic alterations present in the cancer cells. Examples include HER2-targeted drugs for HER2-positive breast cancer and EGFR inhibitors for EGFR-mutated lung cancer.
2. Genomic profiling: This involves analyzing the genetic makeup of a tumor to identify specific mutations or alterations that may be targeted by existing drugs or clinical trials. Genomic profiling helps guide treatment decisions and identify potential therapeutic options that may be effective for the individual patient.
3. Liquid biopsies: Traditional biopsies involve obtaining tissue samples from the tumor site. In contrast, liquid biopsies involve analyzing circulating tumor cells (CTCs) or fragments of tumor DNA (ctDNA) that are released into the bloodstream. Liquid biopsies can provide real-time information about the genetic profile of the tumor, monitor treatment response, and detect potential resistance mechanisms.

Precision medicine has demonstrated significant success in treating various types of cancers, including breast, lung, and prostate cancer. By targeting specific genetic alterations, these treatments can improve patient outcomes and minimize unnecessary exposure to treatments that are unlikely to be effective.

Combination therapy, as you mentioned, is an approach to cancer treatment that involves using two or more different drugs simultaneously or sequentially to enhance the effectiveness of treatment. This strategy aims to target cancer cells through multiple mechanisms, improve response rates, and overcome potential resistance to single-agent therapies. There are several reasons why combination therapy can be more effective than single-agent therapy:

1. Synergistic effects: Certain drugs may have complementary or synergistic effects when used together, meaning their combined action is more potent than the individual effects of each drug. By targeting different pathways or molecular targets within cancer cells, combination therapy can disrupt multiple essential processes, leading to enhanced tumor cell death.
2. Overcoming resistance: Cancer cells can develop resistance to single drugs over time, limiting their effectiveness. By using a combination of drugs with different mechanisms of action, it becomes more difficult for cancer cells to develop resistance simultaneously to all the drugs. This approach can help prevent or delay the emergence of drug resistance and improve treatment outcomes.
3. Improved tumor coverage: Different drugs may have distinct modes of delivery, distribution, or activity within the body. By combining drugs with diverse characteristics, combination therapy can potentially reach and target a broader range of tumor cells throughout the body, including those that may be resistant or less accessible to a single drug.
4. Optimal treatment sequencing: In some cases, sequential administration of drugs in a specific order can lead to improved outcomes. For example, initial treatment with one drug may help shrink the tumor or reduce the number of cancer cells, making the remaining cells more susceptible to the effects of a second drug.

Combination therapy can be used in various ways, such as combining chemotherapy drugs, targeted therapies, immunotherapies, or a combination of these modalities. The specific combination and sequence of drugs depend on factors such as the type of cancer, stage of the disease, the molecular characteristics of the tumor, and individual patient considerations.

Targeted therapy is an important approach in cancer treatment that focuses on specific molecules or pathways involved in the growth and survival of cancer cells. Unlike traditional chemotherapy, which can affect both healthy and cancerous cells, targeted therapy aims to selectively target cancer cells while minimizing damage to normal cells, leading to more precise and potentially less toxic treatment. Targeted therapy drugs are designed to interfere with specific molecules or processes that play crucial roles in cancer development and progression. These targets can include proteins, receptors, enzymes, or genetic mutations that are characteristic of certain types of cancer. By blocking or inhibiting these targets, targeted therapy aims to disrupt the signaling pathways that promote tumor growth and survival.

Key aspects of targeted therapy include:

1. Molecular profiling: Before initiating targeted therapy, patients undergo molecular profiling to identify specific genetic alterations, protein expressions, or other molecular characteristics that can be targeted by available drugs. This helps determine whether a patient is eligible for targeted therapy and guides treatment decisions.
2. Specificity: Targeted therapy drugs are designed to interact with specific targets, such as mutated genes or overexpressed proteins, that are involved in driving cancer growth. By selectively targeting these molecules, the drugs interfere with the specific pathways that cancer cells rely on for survival and proliferation.
3. Types of targeted therapy: There are different types of targeted therapy drugs, including small molecule inhibitors and monoclonal antibodies. Small molecule inhibitors are drugs that can enter cells and interfere with the activity of proteins or enzymes inside the cells. Monoclonal antibodies, on the other hand, are laboratory-produced proteins that can bind to specific molecules on the surface of cancer cells or in the surrounding environment.
4. Combination approaches: Targeted therapy can be used as a standalone treatment or in combination with other treatment modalities such as chemotherapy, radiation therapy, or immunotherapy. Combining different treatment approaches can have a synergistic effect and enhance overall treatment outcomes.

Targeted therapy has demonstrated effectiveness in treating various types of cancers, including breast, lung, colorectal, and many others. Examples of targeted therapy drugs include trastuzumab and pertuzumab for HER2-positive breast cancer, gefitinib and osimertinib for EGFR-mutated lung cancer, and cetuximab for KRAS wild-type colorectal cancer.

Gene therapy

Gene therapy is indeed an innovative approach to cancer treatment that involves the delivery of genetic material into cells to correct or modify their function. In the context of cancer, gene therapy aims to target and manipulate the genes or genetic pathways involved in cancer development and progression. The goal of gene therapy in cancer treatment can vary depending on the specific approach and the characteristics of the cancer. Some potential objectives include:

1. Tumor suppressor gene therapy: Certain genes, called tumor suppressor genes, help regulate cell growth and prevent the formation of tumors. In some cases, these genes may be mutated or inactive in cancer cells. Gene therapy can involve introducing functional copies of these genes into cancer cells to restore their normal function and inhibit tumor growth.
2. Oncogene inhibition: Oncogenes are genes that have the potential to promote cancer development when they are overly active or mutated. Gene therapy can be used to introduce genetic material that inhibits the expression or activity of these oncogenes, reducing their impact on cancer cell growth and survival.
3. Immune system enhancement: Gene therapy can also be employed to enhance the body's immune response against cancer cells. This can involve modifying immune cells, such as T cells, to express chimeric antigen receptors (CARs) that recognize specific proteins on cancer cells. These engineered immune cells can then target and eliminate cancer cells more effectively.
4. Drug sensitization: Gene therapy approaches can be used to make cancer cells more sensitive to certain treatments, such as chemotherapy or radiation therapy. By introducing genes that enhance the cancer cells' susceptibility to specific drugs or therapies, gene therapy aims to improve treatment outcomes.

Gene therapy for cancer is still considered an area of active research and development, and its clinical application is currently more limited compared to other treatment modalities like chemotherapy or radiation therapy. However, there have been notable advancements and promising results in preclinical and early clinical trials, particularly in the field of immunogene therapy.

In addition to the above advancements in cancer treatment, presented below are the selections of the most recent advancements in the realm of immunotherapy pipeline research:

• CAR T-cell therapy: This type of immunotherapy uses genetically modified T cells to attack cancer cells. T cells are a type of white blood cell that play a key role in the immune system. In CAR T-cell therapy, T cells are taken from a patient's blood and then genetically modified to express a chimeric antigen receptor (CAR). The CAR is designed to recognize a specific protein on cancer cells. Once the T cells are infused back into the patient, they can then attack and kill cancer cells that express the target protein. CAR T-cell therapy has shown promising results in clinical trials for a variety of cancers, including leukemia, lymphoma, and myeloma.
• Oncolytic viruses: These viruses are engineered to kill cancer cells while sparing healthy cells. Oncolytic viruses can work in a number of ways. They can directly kill cancer cells by infecting them and causing them to burst. They can also indirectly kill cancer cells by stimulating the immune system to attack them. Oncolytic viruses have shown promise in clinical trials for a variety of cancers, including melanoma, glioblastoma, and pancreatic cancer.
• Immune checkpoint inhibitors: These drugs work by blocking proteins that help cancer cells evade the immune system. These proteins, called checkpoint proteins, help cancer cells hide from the immune system. By blocking checkpoint proteins, immune checkpoint inhibitors can help the immune system recognize and attack cancer cells. Immune checkpoint inhibitors have been approved for the treatment of a variety of cancers, including melanoma, lung cancer, and kidney cancer.
• Cancer vaccines: These vaccines are designed to train the immune system to attack cancer cells. Cancer vaccines can work in a number of ways. They can help the immune system recognize cancer cells that are already present in the body. They can also help the immune system prevent cancer cells from developing in the first place. Cancer vaccines are still in the early stages of development, but they have shown promise in clinical trials for a variety of cancers, including melanoma, cervical cancer, and head and neck cancer.

There are many drug companies that are developing the above therapies. Here are a few examples:

• CAR T cells: Novartis, Kite Pharma, Cellectis, and Bluebird Bio are all developing CAR T cell therapies.
• TCR T cells: Adaptimmune Therapeutics, Cellectis, and TCR2 Therapeutics are all developing TCR T cell therapies.
• Oncolytic viruses: Amgen, Merck, and Teva Pharmaceuticals are all developing oncolytic virus therapies.
• Immune checkpoint inhibitors: Merck, Bristol-Myers Squibb, and Roche are all developing immune checkpoint inhibitor therapies.

These are just a few examples of the many drug companies that are developing immunotherapy therapies. As the field of immunotherapy continues to grow, it is likely that we will see even more companies enter the market.

Here are some additional details about some of the drug companies mentioned above:

• Novartis: Novartis is a Swiss pharmaceutical company that is one of the leading developers of CAR T cell therapies. The company's CAR T cell therapy called Kymriah (tisagenlecleucel) was the first CAR T cell therapy to be approved by the FDA.
• Kite Pharma: Kite Pharma is an American biotechnology company that was acquired by Novartis in 2017. The company is known for its CAR T cell therapy called Yescarta (axicabtagene ciloleucel), which was the second CAR T cell therapy to be approved by the FDA.
• Cellectis: Cellectis is a French biotechnology company that is developing CAR T cell therapies and TCR T cell therapies. The company's CAR T cell therapy called UCART19 is currently in clinical trials.
• Bluebird Bio: Bluebird Bio is an American biotechnology company that is developing CAR T cell therapies and TCR T cell therapies. The company's CAR T cell therapy called Abecma (lisocabtagene maraleucel) is currently in clinical trials.
• Adaptimmune Therapeutics: Adaptimmune Therapeutics is a British biotechnology company that is developing TCR T cell therapies. The company's TCR T cell therapy called ADP-192 is currently in clinical trials.
• Cellectis: Cellectis is a French biotechnology company that is developing oncolytic virus therapies. The company's oncolytic virus therapy called Talimogene laherparepvec (T-VEC) is currently approved by the FDA for the treatment of patients with locally advanced or metastatic melanoma who have not responded to other treatments.
• Amgen: Amgen is an American multinational biopharmaceutical company that is developing oncolytic virus therapies. The company's oncolytic virus therapy called Imlygic (talimogene laherparepvec) is currently in clinical trials for the treatment of head and neck cancer.
• Merck: Merck is an American multinational pharmaceutical and chemical company that is developing immune checkpoint inhibitor therapies. The company's immune checkpoint inhibitor therapy called Keytruda (pembrolizumab) is currently approved by the FDA for the treatment of a variety of cancers, including melanoma, lung cancer, and head and neck cancer.
• Bristol-Myers Squibb: Bristol-Myers Squibb is an American multinational pharmaceutical company that is developing immune checkpoint inhibitor therapies. The company's immune checkpoint inhibitor therapy called Opdivo (nivolumab) is currently approved by the FDA for the treatment of a variety of cancers, including melanoma, lung cancer, and kidney cancer.
• Roche: Roche is a Swiss multinational healthcare company that is developing immune checkpoint inhibitor therapies. The company's immune checkpoint inhibitor therapy called Tecentriq (atezolizumab) is currently approved by the FDA for the treatment of a variety of cancers, including lung cancer, bladder cancer, and head and neck cancer.

These are just a few examples of the many drug companies that are developing immunotherapy therapies. As the field of immunotherapy continues to grow, it is likely that we will see even more companies enter the market. Likely dates of launch of these therapies vary depending on the therapy and the regulatory approval process.

• CAR T-cell therapy: CAR T-cell therapy has already been approved for use in some patients with leukemia and lymphoma. It is possible that CAR T-cell therapy could be approved for use in other types of cancer in the next few years.
• Immunotherapy: Immunotherapy has already been approved for use in some patients with melanoma, lung cancer, and colorectal cancer. It is possible that immunotherapy could be approved for use in other types of cancer in the next few years.
• Gene therapy: Gene therapy is still in the early stages of development, but it is possible that gene therapy could be approved for use in patients with cancer in the next 5 to 10 years.
• Nanoparticles: Nanoparticles are still in the early stages of development, but it is possible that nanoparticles could be approved for use in patients with cancer in the next 5 to 10 years.

For more information, please contact us at info@cliniminds.com or call us at +91 95601 02589 or +91 93014 85978.

Overview of United Kingdom Clinical Trials Market

 

Market Size and Growth:

• The UK clinical trials market was valued at £2.3 billion in 2022 and is projected to reach £3.2 billion by 2028, growing at a CAGR of 5.1%.
• This growth is driven by factors like:
• Clinical trials: Involve testing the drug on human volunteers in a series of meticulously designed phases:
  • Strong national health system (NHS) infrastructure
  • High patient participation rates
  • Expertise in research and development
  • Government initiatives to support clinical trials

Key Players:

• Pharmaceutical and biopharmaceutical companies: Global giants like GSK, AstraZeneca, and Roche have significant presence alongside smaller UK-based companies.
• Contract research organizations (CROs): Iqvia, Syneos Health, and Parexel hold major shares, with local players like Oxford Clinical Research Unit gaining traction.
• Clinical research sites: NHS hospitals, academic medical centers, and specialist research institutes like the NIHR Clinical Research Network play a vital role.
• Technology and data analytics companies: Companies like Medidata Solutions and Veeva Systems offer solutions for trial management and data analysis.

Number of People Employed:

Several key players contribute to the success of clinical research:

• Estimates suggest 200,000 people are directly or indirectly employed in the UK clinical trials market, accounting for around 3% of the global workforce.
• This includes researchers, clinicians, nurses, data analysts, and administrative personnel.

Key Trends:

• Decentralized clinical trials: Increasing focus on community settings and telehealth to improve patient access and participation.
• Focus on rare diseases and personalized medicine: Addressing unmet medical needs and tailoring treatments to individual patients.
• Adoption of digital technologies: Using telemedicine, wearables, and e-consent platforms to enhance trial efficiency and engagement.
• Increased data sharing and collaboration: Initiatives like the UK Digital Health and Care Data Strategy aim to facilitate research collaboration.
• Emphasis on patient-centricity: Involving patients in trial design, decision-making, and outcome reporting.
• The UK maintains a leading position in Phase I clinical trials globally but lags other European countries in Phase II and III studies.
• Oncology and neuroscience are the leading therapeutic areas for clinical trials in the UK.
• The future of the UK clinical market hinges on addressing challenges like talent shortages, navigating the post-Brexit landscape, and maintaining competitiveness in the global arena.

Effects of Brexit on the UK Clinical Market:

• Changes in regulatory landscape: The Medicines and Healthcare products Regulatory Agency (MHRA) has replaced the European Medicines Agency (EMA) for drug approvals, creating some initial uncertainty.
• Potential impact on patient recruitment: Concerns about UK trial participation in European research networks, though initiatives like Horizon Europe aim to maintain collaboration.
• Opportunities for domestic growth: Potential increase in government funding and focus on UK-based clinical trials.

Overview of the Indian Clinical Trials Market

 

Market Size and Growth:

The Indian clinical trials market is booming, currently valued at USD 1.55 billion and projected to reach USD 8.36 billion by 2029, growing at a CAGR of 8.64%. This impressive growth is driven by several factors:

• Large and diverse patient population: With over 1.3 billion people, India offers a vast pool of participants for diverse clinical trials.
• Cost-effectiveness: Conducting trials in India is significantly cheaper compared to Western countries, attracting global pharmaceutical companies.
• Regulatory ease: Streamlined approval processes and recent amendments to the New Drugs and Clinical Trials (NDCT) Rules have simplified the conduct of trials.
• Rising R&D investment: Both domestic and international pharmaceutical companies are increasing R&D spending in India, leading to more clinical trials.
• Skilled workforce: A growing pool of scientists, doctors, and research professionals ensures high-quality trial execution.

Key Players:

Several key players contribute to the success of clinical research:

• Domestic pharmaceutical companies: Cipla, Sun Pharma, and Dr. Reddy's Laboratories are actively involved in clinical trials.
• International pharmaceutical companies: Global giants like Pfizer, Novartis, and Roche are increasingly conducting trials in India.
• Contract research organizations (CROs): International CROs like Parexel and Iqvia, along with domestic players like Syngene International and Acumen Research, provide critical support.
• Clinical research sites: Leading hospitals, medical colleges, and research institutes form the backbone of the clinical trial infrastructure.

Number of People Employed:

Estimates suggest over 300,000 people are directly or indirectly employed in the Indian clinical trials market. This includes researchers, clinicians, nurses, data analysts, project managers, and administrative personnel. The demand for skilled professionals is expected to rise further, creating significant job opportunities.

Key Trends:

• Decentralized clinical trials: Increasingly popular, reaching patients in rural areas and improving access to trials.
• Focus on therapeutic areas: Oncology, diabetes, infectious diseases, and cardiovascular diseases are leading areas for clinical trials.
• Adoption of digital technologies: AI-powered platforms, telemedicine, and e-consent are enhancing trial efficiency and data management.
• Increasing patient participation: Awareness campaigns and improved ethical practices are boosting patient engagement.
• Focus on quality and compliance: Stringent regulatory oversight and international collaborations are improving trial quality and safety.
• India holds a significant position in the global clinical trials market, accounting for around 8% of global trial activity.
• The government is actively promoting clinical research through initiatives like the National Clinical Research Network.
• Ethical considerations and patient protection remain crucial areas of focus to ensure responsible and sustainable growth in the market.

The Indian clinical trials market presents a promising and dynamic landscape for research and development. Understanding the key trends and challenges will be crucial for both domestic and international players to navigate this rapidly evolving market effectively.

Overview of China's Clinical Trials Market

 

Market Size and Growth:

• The Chinese clinical trials market is on a meteoric rise, currently valued at USD 40 billion and projected to reach USD 82 billion by 2028, with a CAGR of 14.9%.
• This impressive growth is fueled by:
• Clinical trials: Involve testing the drug on human volunteers in a series of meticulously designed phases:
  • A massive and increasingly affluent population (1.4 billion+) presenting a huge patient pool.
  • Rising R&D expenditure in pharma and biotechnology, with China becoming a global R&D hub.
  • Government initiatives to streamline regulations and incentivize clinical trials.
  • Rapidly growing healthcare infrastructure and skilled clinical research professionals.

Key Players:

• Domestic pharmaceutical companies: Local giants like Huahai and Zheijiang Hisun control a significant share, competing with global players like Roche and Merck.
• International pharmaceutical companies: Increasingly conducting trials in China due to the potential market size and faster approval processes.
• Contract research organizations (CROs): Both international (IQVIA, Parexel) and domestic (WuXi AppTec, CRO Clinical Trial Center) play crucial roles.
• Clinical research sites: Over 29,000 hospitals and 1 million+ independent clinics offer diverse sites, including top academic medical centers.

Number of People Employed:

• Estimates suggest over 1.5 million people work in the clinical trials market directly or indirectly.
• This includes researchers, clinicians, nurses, data analysts, project managers, and administrative personnel.
• The demand for skilled professionals is high, creating significant job opportunities.

Key Trends:

• Decentralized clinical trials: Gaining traction to improve patient access and trial diversity, reaching beyond major cities.
• Focus on innovative therapies: China holds a prominent position in gene therapy and cell therapy trials, alongside traditional drug categories.
• Adoption of digital technologies: Telemedicine, AI-powered platforms, and e-consent are increasingly utilized for enhanced efficiency and data management.
• Data sharing and collaboration: Government initiatives promote data sharing platforms and international partnerships to drive research.
• Emphasis on patient-centricity: Patient awareness, engagement, and informed consent are becoming increasingly important.

Additional Points:

• China accounts for nearly 28% of global clinical trial activity, showcasing its global significance.
• The focus is shifting towards high-value trials in specialized areas like oncology, rare diseases, and precision medicine.
• Intellectual property and data security remain considerations for foreign companies conducting trials in China.

China's clinical trials market offers immense potential and is rapidly evolving. Navigating the complexities and staying updated on the latest trends will be crucial for success in this dynamic landscape.

Segmented Overview of the Latin American (South American) Clinical Trials Market

 

Overall Market Size and Growth:

Drug development starts with identifying a target molecule and progresses through various stages:

• The combined South American clinical trials market is valued at USD 5-8 billion as of 2023 and is projected to reach USD 14-20 billion by 2030, growing at a CAGR of 8-12%.

Key Drivers of Growth:

• Large and diverse population: South America boasts over 400 million people, offering a sizeable and diverse patient pool for clinical trials.
• Rising R&D spending: Both local and international pharmaceutical companies are increasing R&D investments in the region, leading to more trials.
• Cost-effectiveness: Conducting trials in South America can be significantly cheaper than in North America or Europe, attracting sponsors.
• Streamlined regulations: Several countries have implemented regulatory reforms to simplify and expedite the approval process for clinical trials.
• Improving healthcare infrastructure: The South American healthcare system is rapidly evolving, with modern hospitals and skilled medical professionals.

Market Breakdown by Country:

Country	Market Size (USD billion)	Key Players
Brazil	>9	Grupo Biosintética, Bio-R, Pfizer, Novartis, Roche
Argentina	1.5-2	Chemo, Instituto Leloir, Merck, Sanofi
Mexico	1-1.5	Praxis Clinical Research, Quintiles, AstraZeneca, GSK
Colombia	0.5-1	Clinica Palermo, Fundacion Oftalmologica Nacional, Eli Lilly, Janssen
Chile	0.5-1	Clinical Research Chile, Universidad de Chile, Abbott, Bayer

Number of People Employed:

• Although precise figures are unavailable, estimates suggest over 500,000 people are directly or indirectly employed in the South American clinical trials market. This includes researchers, clinicians, nurses, data analysts, project managers, and administrative personnel.

Key Trends:

• Decentralized clinical trials: Reaching patients in rural areas and improving access to trials across the region.
• Focus on regional health priorities: Infectious diseases, neglected tropical diseases, and chronic diseases like cancer and cardiovascular diseases are leading areas for clinical trials.
• Adoption of digital technologies: Telemedicine, AI-powered platforms, and e-consent are increasing efficiency and data management.
• Growing emphasis on ethics and patient protection: Stringent regulations and ethical awareness campaigns are becoming more prevalent.
• Regional and international collaboration: Initiatives like PANVAC and ICTRP are promoting collaboration and data sharing.

Challenges:

The clinical research landscape offers diverse career opportunities, including:

• Varied regulatory landscape: Each country has its own regulations, requiring careful navigation by sponsors and CROs.
• Logistics and infrastructure: Challenges with transportation, communication, and healthcare infrastructure in some regions can hinder trial conduct.
• Skilled workforce shortages: The demand for trained and experienced professionals in clinical research outpaces the supply in some countries.

Further Insights:

• Brazil: Largest market, strong local pharmaceutical industry, focuses on cancer and infectious diseases.
• Argentina: Strong academic research base, expertise in oncology and chronic diseases.
• Mexico: Cost-effective option, rising interest in rare diseases, government initiatives to promote clinical trials.
• Colombia: Strong patient recruitment rates, focus on personalized medicine and ethical considerations.
• Chile: Emerging market, clinical trial tourism potential, focus on rare diseases and academic research.

Multinational Pharma Companies Involved in Clinical Trials

Pharma Data Analytics - Opening Doors to a New Vertical In Healthcare

The pharmaceutical industry is currently ranked as 2nd on the global scale with a market of estimated US $874 billion which would exponentially soar to US $ 1.22 trillion by 2022, the key drivers for this high stake is mainly due to poly-therapy used in the treatment of multiple chronic conditions like hypertension, diabetes, COPD, hyperlipedmia.

The healthcare system of India is growing at an incredible pace with a current compounded annual growth rate of (CAGR) of 22.9 % which is expected to reach a net worth of USD 150 Billion by 2020.

With easy accessibility of medicines, better nutritional supplements, better formulations and the switch from supervised to self-therapies using engineered technologies like controlled delivery systems, has impacted the pharmaceutical market to a great extent globally.

This impact has also led to many changes in the regulatory framework for instance, with respect to compliance, the marketing authorization holders (MAH) have been asked to focus more on the outcome, rather than the input Irrespective of whether MAH has a robust pharmacovigilance system in place, if the risk of a drug causing a Serious Adverse Reaction which may also be life threatening is not controlled through implementation of risk mitigation strategies, it may lead to reactive measures which may include complete withdrawal of drug from the pharmaceutical market.

Through the use of Digital/social media platforms like facebook, twitter, blog spot has led people to take health related decisions. Data from such websites when mined and analysed using predictive analytical solutions would help in understanding the patient needs and accordingly this data may be applied in understanding the current market share of the product.

Pharma analytics is a science which provides data insights through reporting, descriptive, predictive and prescriptive analytical solutions. Pharma analytics helps companies to understand current trends in pharmaceutical space.

Its core components comprises of Drug discovery analytics, Supply disruption predictiveanalytics, Product failure analytics which uses predictive analysis to understand product failures, Risk analytics used in understanding the benefit vs risk how the well risk be tolerated in a study population, Social analytics to understand the actual need of the drug in the population. Pharma analytics also enhances reporting systems to ensure effective communication and adherence to regulatory compliance. The use of Business intelligence Visualization software enables better analysis of the business data.

Direct to customer selling, aggressive marketing strategies and launch of a molecules in many countries at the same time has led the MAH to highly depend on analytics for e.g. Pharma analytics is now been profusely used in the reduction of cycle time for clinical trials.

Analytical systems are designed in such a way that they are self-learning, evolving as per feedback received from end users. Lifesciences organisations are now relying on decision made using analytical tools, Pharma analytics thus promises a huge scope in the coming years.

For more information on the career in pharma data analytics, please contact info@cliniminds.com or call +91 98100 68241.

References:

Analytics

1. Analytics in Pharma and Life Sciences; Abhishek Menon, Anupam Jain; Everest group research; page 3,6,7,9

Weblink:http://www.genpact.com/docs/default-source/resource-/analytics-in-pharma-and-life-sciences

(Last accessed on 29 Dec 2017; 16:00)

2. Life Sciences

Weblink: https://www.infosys.com/data-analytics/verticals/Pages/life-sciences.aspx

(Last accessed on 29 Dec 2017; 16:15)

3. Pharmaceutical Commerce; “Global pharma market will reach $1.12 trillion in 2022”; September 26, 2016

Weblink: http://pharmaceuticalcommerce.com/business-and-finance/global-pharma-market-will-reach-1-12-trillion-2022/

(Last accessed on 29 Dec 2017; 16:15)

Cliniminds Education Loans

Education Loans for Cliniminds Students

Cliniminds – www.cliniminds.com is pleased to announce the partnership with ‘difin’, a leading education loans copany – www.difin.in to offer education loans to the students interested in enrolling for Cliniminds educational programs. Loans are available for both classroom and online programs.

Loans are available for both working professionals and non-working graduates and post graduates aspiring to pursue further education. Difin are making education affordable.

For more information, please contact info@cliniminds.com or +91 9910068241; 9560665441